AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.
- Milestone payment unlocks new clinical data from China trials
- Secures proprietary materials for local manufacturing transfer
- First Australian manufacturing runs expected late 2026
- Preparing for pre-IND FDA meeting in second half 2026
- Solid cancer CAR-T approval in China validates strategy
Milestone Payment Advances BZDS1901 Development
AdAlta Limited (ASX:1AD) has made a US$1 million milestone payment to Shanghai Cell Therapy Group, fulfilling its initial financial obligations under their Development and Collaboration Agreement for BZDS1901, a CAR-T therapy targeting advanced mesothelioma. This payment, partly funded by a recent A$2.5 million placement, grants AdAlta access to additional clinical data from investigator-initiated trials in China and secures critical proprietary materials essential for manufacturing BZDS1901 in Australia.
CEO Dr Tim Oldham highlighted that completing this financial commitment reflects strong shareholder support and allows the company to focus on building Australian manufacturing capabilities and engaging with the US Food and Drug Administration (FDA), the next significant milestones for the program's value.
Access to Clinical Data and Manufacturing Materials
The milestone unlocks ongoing treatment durability data and CAR-T cell expansion and persistence information from five additional advanced mesothelioma patients treated with BZDS1901 in China. This data will inform future regulatory submissions and clinical development plans.
Crucially, the payment also secures supply of proprietary plasmid DNA and mRNA transposases from Shanghai Cell Therapy Group. These genetic blueprints and tools are necessary to engineer patients’ immune cells into cancer-fighting CAR-T cells, and securing them is a prerequisite for transferring manufacturing to Australia.
Manufacturing Transfer and Regulatory Engagement
Technology transfer to Cell Therapies Pty Ltd (CTPL) is underway, with the first Australian manufacturing runs expected in the second half of 2026. This step is vital for establishing local production capacity, which enhances scalability and regulatory compliance.
Simultaneously, AdAlta is preparing for a pre-Investigational New Drug (pre-IND) meeting with the US FDA, also anticipated in the latter half of 2026. This engagement aims to align clinical and manufacturing strategies with FDA expectations, potentially accelerating BZDS1901’s path to market.
Validation from China's First Solid Cancer CAR-T Approval
The recent approval of Satri-cel by CARsgen Therapeutics in China, the world’s first CAR-T product for solid tumors, validates AdAlta’s “East to West” strategy. Satri-cel demonstrated a more than 20% overall response rate in Claudin18.2-positive advanced gastric cancers, a significant improvement over control treatments.
This milestone underscores China’s leadership in solid cancer CAR-T innovation and supports AdAlta’s belief in the clinical potential of CAR-T therapies in solid tumors, including mesothelioma, where BZDS1901 has shown promising response rates and survival outcomes.
Clinical Promise in Mesothelioma
Mesothelioma remains a rare but aggressive cancer with limited treatment options beyond first-line chemotherapy or immunotherapy. Current therapies yield modest tumour shrinkage rates and survival times.
By contrast, BZDS1901 has reported up to 50% overall response rates and 20% complete response rates in relapsed or advanced mesothelioma patients in China, with median overall survival not yet reached in ongoing studies. These results suggest BZDS1901 could offer a meaningful new option for patients with few alternatives.
AdAlta’s approach integrates Asia’s innovation in CAR-T development with Australia’s manufacturing and regulatory environment, aiming to efficiently bring novel cellular immunotherapies to Western markets.
Bottom Line?
AdAlta’s milestone payment clears the way for Australian manufacturing and FDA dialogue, setting a critical runway for BZDS1901’s clinical and commercial progress.
Questions in the middle?
- How will the additional clinical data from China influence FDA regulatory strategy?
- What challenges might arise in scaling Australian manufacturing for BZDS1901?
- Can AdAlta leverage its East to West model to accelerate approvals beyond mesothelioma?